4 Active Stocks to Watch Today 🔥

Good Morning! Hey, there! It's Chris from Elite Trade Club, here to give you this morning's premarket trading news. Today is Tuesday, November 7th. I hope you have a great day. Now, let's get ready to trade! Markets 📈 Stocks opened the week with a mixed performance on Monday. Large-cap indexes advanced, with the Dow and S&P 500 gaining 0.1%, while the Nasdaq added 0.3%. The small-cap Russell 2K sold off for a 1.2% loss. Today, S&P 500 futures are down 0.2% in early trading, which could indicate we're heading for a lower open after several days of gains. Sponsored [Trillion Dollar Honey-Hole "Hiding in Plain Sight"]( "Honey-Hole" is slang for a location that yields a valued commodity or resource. And AI is that commodity. Statista currently value's the AI sector at $100 billion, and expects that number to explode by twenty-fold by 2030, placing its potential value at $2 trillion in under seven years. But which AI company is the best investment? We compiled a list of our Top 5 AI Stocks. [ Click Here for Details]( Premarket Highlights 🔎 📉 Oil Prices Hit the Skids Gear up, road trippers and market-watchers! Oil's taking a bit of a tumble, sliding to prices we've not seen since the leaves started changing colors. It's a hint that our global thirst for energy might be hitting a bit of a... yawn. Dipping Down 📉 Brent Crude's dance number is a couple of steps back, dipping nearly 2% to a humble $84 a barrel. Meanwhile, West Texas Intermediate is strutting below $80, feeling all August-like. War & Prices? Not This Time 💥 Remember those price hikes when tensions flared in the Middle East? Well, they've vanished like a mirage. Pump prices are taking a breather, too, with a gallon of regular now lounging at $3.40, down from $3.72 just a month ago. So go ahead, fill 'er up! What's Behind the Wheel? 🚗 A pumped-up dollar and interest rates reaching for the sky are putting the brakes on oil demand, with emerging markets and Japan easing off the gas pedal. Despite the Middle East conflict headlines, the oil flow's as smooth as your favorite playlist on a long drive. So buckle up, energy enthusiasts. We might be in for a more budget-friendly cruise as oil prices hit the skids. What to Watch Today 👀 Economic Data Q3 Earnings are still rolling in, and they should be on your radar. But, today, I think the economic schedule could provide more valuable insights. Consumer credit could give us a feel for what to expect this holiday season. Highly-leveraged shoppers could deliver a less-than-stellar holiday shopping season, so I will be interested to see how these numbers look. Also, be on the look out for the trade deficit report to see how U.S. trade progressed in September. Major Earnings 💰 Uber Technologies [UBER] ... AM Air Products And Chemicals [APD] ... AM KKR [KKR] ... AM Emerson Electric Company [EMR] ... AM D.R. Horton [DHI] ... AM Fidelity National Information Services [FIS] ... AM Gilead Sciences [GILD] ... PM Occidental Petroleum Corporation [OXY] ... PM Devon Energy Corporation [DVN] ... PM Coupang [CPNG] ... PM Economy 🏗 - U.S. trade deficit [Sep] ... 8:30a - Consumer credit [Sep] ... 3:00p Running Hot 🔥 Gainers - Tharimmune [THAR] >> +80.6% - Ault Alliance [AULT] >> +21.5% - Olaplex [OLPX] >> +25.3% Decliners - Ventxy Bio [VTYX] >> (76.5%) - Alto Ingredients [ALTO] >> (47.3%) - CalciMedica [CALC] >> (27.1%) Intl. Flavors & Fragrances [IFF] - Last Close: $72.34 Earnings are boosting shares of IFF. The industrial conglomerate reported its Q3 results after yesterday's close, and investors liked what they saw. IFF reported EPS of $0.89 against the consensus of $0.75. However, it was a drastic drop-off from last year's Q3 bottom-line EPS figure of $1.36. Sales also fell to $2.82 billion from $3.06 billion a year ago, but still managed to top the consensus of $2.76 billion. IFF also affirmed full-year 2023 sales guidance that was in-line with analysts' estimates. IFF is leading the S&P 500 in early trading with a 3.0% gain. My Take: Seeing lots of YoY sales declines this earnings season, but IFF appears to be managing the downturn well. It's a sign of a well managed company. TransMedics [TMDX] - Last Close: $40.19 TransMedics is getting a boost from a big earnings beat. The company released its Q3 earnings results late Monday and exceeded Wall Street's expectations. TransMedica reported a wider-than-expected loss of ($0.78) per share and fell short of analysts' estimate of a ($0.19). However, things brightened up from there. Revenues more than double from last year to $66.4 million and easily beat the $49.2 million consensus. TransMedics also hiked its full-year revenue guidance in light of the strong quarter. Shares of TMDX are up 44.3% in early trading. My Take: TMDX began to rebound last week after a long sell-off. Trading volume also spiked, and now it's getting another boost from this earnings report. This could be the early phases of a pivot. Carbon Revolution [CREV] - Last Close: $87.37 Carbon Revolution is skyrocketing after a SPAC merger. The OEM supplier of advanced carbon fiber wheels completed its business combination with Twin Ridge SPAC last Friday, and it's been soaring ever since. On Friday, the stock officially began trading on the NASDAQ-NMS under the symbol CREV, dropping its former ticker symbol of TRCA. Yesterday, it got another big boost when it announced the receipt of a $70 million equity investment from Orion Infrastructure Capital. Shares soared 197.9% on Monday following the news, and they're still running hot in the premarket. CREV is up 44.4% in early trading. My Take: Not sure what's going on here. It's been very volatile and somehow I don't think a tire-maker is worth all the hype. I see a sudden pullback somewhere down the line for this stock. Senti Bio [SNTI] - Last Close: $0.2920 Senti Bio is rallying after an announcement After Monday's close, the tiny biotech unveiled a new strategic collaboration with Celest Therapeutics for the clinical development of Senti-301 in China. Under the terms of the deal, Senti is eligible to receive up to $156 million in milestone and royalty payments. Celest will lead clinical development, operations, and manufacturing for the advancement of SENTI-301A with technical support from Senti Bio. Senti Bio will retain all commercialization rights outside of mainland China, Hong Kong, Macau, and Taiwan for SENTI-301A. SNTI is up 133.3% on active trading volume in response to the deal. My Take: This could be a big deal for SNTI if the royalty payments get triggered, but it could take quite a while for the catalyst to materialize. That's it for today! Thanks for reading, and good luck out there! Best Regards, Chris D. -- Elite Trade Club P.S... Want alerts delivered straight to your cell every morning for free?* Text ELITE to 47121 to sign up now and get our watchlists sent directly to your phone! Or text CLOSE to 47121 to get on the mobile alert list for our Closing Bell Roundup report, featuring the day's top winners and losers. *Standard message/carrier rates may apply. Legal Stuff: Stocks featured in this newsletter are for entertainment purposes only. You should not base any investment decisions on information contained in my newsletter. Stocks featured in this newsletter may be owned by owners/operators of this website which could impact our ability to remain unbiased. Please consult a financial advisor before making any trading decisions. I may earn a small commission from links placed inside of these emails. [Bots click here]( 1969 S. ALAFAYA TRAIL Orlando FL 32828 USA [Unsubscribe]( | [Change Subscriber Options](